Novartis to Buy Myricx Bio for Up to $1.5 Billion
Novartis has announced a deal to acquire UK-based cancer biotech firm Myricx Bio for as much as $1.5 billion.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Novartis is moving to acquire the UK-based biotechnology firm Myricx Bio. The agreement involves an upfront payment of $1.1 billion, with total potential compensation reaching $1.5 billion.
Coverage from outlets including Reuters, the Financial Times, Bloomberg, the Wall Street Journal, and Fierce Biotech highlights the acquisition as a strategic expansion of Novartis’s antibody-drug conjugate (ADC) pipeline. Sofinnova Partners confirmed the agreement in a business wire release.
Future developments depend on the formal closing of the transaction. Coverage does not yet specify a final completion date for the deal.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 3h ago.
Quick answers
What is the total value of the acquisition?
The deal is valued at up to $1.5 billion.
How much of the payment is upfront?
Novartis is set to pay $1.1 billion upfront.
What is the primary focus of Myricx Bio?
Myricx Bio is a UK-based biotech company specializing in cancer research and antibody-drug conjugates.
Coverage (8)
- Four major biotech updates to catch up on STAT · 11h ago
- Novartis to acquire UK-based Myricx Bio for up to $1.5 billion Reuters · 11h ago
- Novartis acquires U.K. cancer biotech Myricx Bio for $1.5 billion qz.com · 11h ago
- Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis Business Wire · 11h ago
- Novartis to buy UK biotech Myricx Bio in $1.5bn deal Financial Times · 11h ago
- Novartis to pay $1.1B upfront for Myricx to expand ADC pipeline Fierce Biotech · 11h ago
- Novartis to Buy Cancer-Drug Firm Myricx for Up to $1.5 Billion Bloomberg.com · 11h ago
- Novartis to Buy Myricx Bio for Up to $1.5 Billion WSJ · 11h ago
Topics
Related trends
Uber stalls European food delivery push as it pursues Delivery Hero takeover
Uber stalls European food delivery growth to pursue a potential takeover of Delivery Hero.
How a new fungal genome-editing tool could open fresh paths to cancer treatments
A prime‑editing tool for filamentous fungi is producing novel anti‑cancer compounds, drawing biotech attention.
Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs
Scribe Therapeutics seeks $75 million in an IPO, testing market appetite for early-stage biotech.
‘World’s most contagious disease’ on track for highest US cases in 35 years
Measles cases in the United States have surpassed 2,000 in 2026, threatening the nation's measles-free status as infections reach a 35-year high.
Kroger to purchase Giant Eagle for $1.65 billion
Kroger has entered into an agreement to acquire the supermarket chain Giant Eagle in a transaction valued at approximately $1.65 billion.
FDA’s top gene therapy regulator is leaving his role
11 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.